Please login to the form below

Not currently logged in
Email:
Password:

Nile Therapeutics heart drug fast-tracked

The US Food and Drug Administration (FDA) has awarded fast-track status to Nile Therapeutics' development programme for heart drug cenderitide
The US Food and Drug Administration (FDA) has awarded fast-track status to Nile Therapeutics' development programme for cenderitide aimed at reducing mortality after heart failure. The novel indication is being referred to as "post-acute", according to the company. 

Specifically, Nile is developing the drug to reduce cardiovascular mortality and cardiovascular re-hospitalisation in the post-acute period in patients with acute decompensated heart failure. 

Nile plans to develop cenderitide as an outpatient therapy to be delivered continuously through a subcutaneous pump for up to 90 days after discharge from the hospital. The company said it believes the drug will provide patients with sustained symptomatic relief that could significantly reduce post-acute re-hospitalisations.

Fast-track status, which is reserved for drugs that have the potential to treat serious diseases and fill unmet medical needs, allows for a rolling submission and review of the marketing application, as well as more frequent feedback from the FDA.

Cenderitide, Nile's lead product, is a novel rationally designed chimeric peptide that was created by scientists at the Mayo Clinic. 

31st March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics